The use of biological therapy (BT) in rheumatoid arthritis (RA) has supposes a very important change in the disease's treatment and prognosis. Drugs like Anti-TNFα have proven unquestionable effectiveness. However, the lack or loss of such effectiveness over time raises the dilemma of what factors may influence it. There are studies that suggest the influence of BMI on the efficacy of these drugs and therefore on the control of the disease. Objectives: To determine the influence of BMI on disease activity and response to treatment with infliximab (ifx) in patients with RA. Methods: A retrospective observational study of a population of 76 patients with RA who received infliximab treatment, in a standard guideline of 3 mg/kg, in our service between 2000 and 2016 inclusive. The BMI was classified for some sub-studies in four categories: low (<18.5), normal (=18.5-<25), overweight (=25-<30) and obesity (=30). Disease activity was determined by DAS28 at three times: at baseline, at 6 months and at the year of infliximab treatment; Response to treatment was assessed by deltaDAS28 and EULAR response at 6 months and 1 year of treatment. The EULAR response was classified into two categories: "yes" (DeltaDAS28>1.2, or>0.6 and DAS28 <5.1) and "no" (DeltaDAS28 <.6, or <5.1). First, activity and response rates to treatment were compared in these four groups over the three periods. A regression analysis was then performed for BMI and both activity and response to treatment. Results: Characteristics of the 76 patients included in the study when initiating IFX therapy were: 66 (86.8%) were women, median (range) age 54 (21-83) years, 77,% RF+, 81% ACPA+, disease duration 10,8 (1,0-39,0) years, 59% with concomitant methotrexate and 55% with other DMARDs. Median (range) BMI was 25,5 (16,7-40,2) kg/m 2 . According to BMI, patients with underweight, normal, overweight and obesity were 0 (0,0%), 41 (53,9%), 22 (28,9%) and 13 (17,2%), respectively. The association between BMI and disease activity (median DAS28 (p25-p75)) is shown in Table 1: 
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Normal Overweight Obesity DAS28 bas 5, 30) 5, 44 (4, 73) 6, 25 (4, 07) DAS28 6m 3, 90 (2, 97 (3, 43) 4, 80 (3, 72) DAS28 1y 3, 91 (2, 01) 3, 69 (2, 29) 4, 48 (2, 87) The association between BMI and treatment response (median deltaDAS28 (p25-p75) and EULAR response (%)) is shown in Table 2 : In the longitudinal analysis, a trending but not statistically significant relationship between adjusted BMI and DAS28 was observed at six month and at one year of treatment onset: β: 0,051; 95% CI (-0,06 to 0,109) and β: 0,037; 95% CI (-0,022 to 0,097) 
Background:
In phase 1 trials (NCT01534884 and NCT01873443), pharmacokinetic equivalence of CT-P10, biosimilar of rituximab, to innovator rituximab (RTX) was demonstrated. In the phase 3 study, equivalence of PK and efficacy up to week 24 were achieved between CT-P10 and RTX (US and EU sourced) 1,2 . Objectives: To investigate the long-term efficacy, pharmacodynamics, immunogenicity and safety of CT-P10 up to week 48. Methods: Patients with rheumatoid arthritis were randomly assigned to CT-P10, US-RTX or EU-RTX, in combination with MTX. The patients received 2 treatment courses at Week 0 and 24, each consisting of 2 infusions of 1000mg study drug at 2-week interval. Results: A total of 372 patients were randomised, and 330 patients completed the 2nd course treatment. DAS28 scores through Week 48 were comparable between CT-P10 and US/EU-RTX ( Figure) , as well as the proportion of ACR responses at Week 48 between the CT-P10 and combined rituximab groups; 81.3% and 79.8% for ACR 20, 55.4% and 53.9% for ACR50, and 31.7% and 33.7% for ACR 70, respectively. B-cell depletion was comparable from after the 1st infusion and up to Week 48. Number (%) of patients with positive anti-drug antibodies in the CT-P10, US-RTX, and EU-RTX was 7 (4.9), 13 (9.4), and 5 (8.6), respectively at Week 48. The safety profile was also similar across groups (Table) . Objectives: To study the correlation between levels of the anti-TNF biologics and clinical efficacy in patients with inflammatory arthritis Methods: Adult patients who fulfilled the criteria for rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PSA) and were commenced on standard doses of the anti-TNF biologics were recruited. Serum samples saved at baseline, month 6 and 12 were assayed for the trough levels of the biologics (± anti-drug antibodies) retrospectively. Patients were followed longitudinally and efficacy analyses were conducted at 3-month intervals without the knowledge of the drug levels. Biologics would be discontinued from 6 months onwards according to protocol-based improvement criteria for each disease. Clinical efficacy of the anti-TNF biologics was compared among patients with different levels of the drug by statistical methods. Results: 112 patients were studied (58 RA, age 51.2±10.9 years, disease duration 72.9±67 months; 41 SpA, age 39.1±9.9 years, disease duration 74.3±81.6 months; 13 PSA, age 53.5±10.7 years, disease duration 44.3±35.4 years). The number of patients treated with infliximab (IFX), adalimumab (ADM), golimumab (GLM) and etanercept was 3, 31, 36 and 42, respectively. At month 12, neutralizing antibodies against IFX, ADM and GLM were present in 2 (67%), 14 (45%) and 1 (3%) of the patients, respectively. In ADM users, the drug level was significantly lower in those with antibodies than those without (1.81±2.63 vs 8.02±4.14 ug/ml; p<0.001). Antibody titer against ADM correlated negatively with the levels of ADM (Rho -0.72; p<0.001). Patients were stratified arbitrarily into 3 groups for each biologic according to the trough levels of the drugs. Low drug concentrations were defined as levels ≤1.30 ug/ml, 0.05 ug/ml and 0.60 ug/ml in ADM, ETN and GLM users, respectively. In patients with RA/PSA (N=71), patients with the lowest anti-TNF drug level group (N=30) had a non-significant trend of less improvement in DAS28, CDAI scores at month 12 when compared to others (N=41). However, significantly more patients withdrew treatment due to inefficacy at month 12 in this group compared to others (67% vs 7.3%, p<0.001). In patients with SpA (N=41), patients with lowest anti-TNF drug levels stratum (N=9) had significantly less improvement in ASDAS compared with others at month 12 (N=32) (-0.57±0.63 vs -1.93±1.28; p=0.003). The proportion of patients who achieved an ASAS20 response was also significantly lower in this group of patients (33% vs 75%; p=0.04). In all the 112 patients studied, the cumulative withdrawal rate of the anti-TNF biologics at month 12 (by Kaplan-Meier's analysis) was significantly higher in those with low drug levels when compared to others (26.1% vs 54.6%; p<0.001 by log rank test).
Conclusions:
The presence of neutralizing antibodies to the anti-TNF monoclonals is associated with lower trough levels of the drugs. [2011] [2012] [2013] [2014] to study adult RA individuals previously treated with methotrexate (oral or SQ) and newly prescribed one of the medications under study. The date of first filled prescription or infusion drug was defined as the cohort entry and a 12-month pre-period was used to exclude prior users of biologics or tofacitinib. We required subjects to be continuously enrolled in the medical and pharmacy plan 12 months before and after the cohort entry. Effectiveness was access through an algorithm previously validated 1 , based on the following criteria: 1) non-adherence; 2) switching/adding a new biologic or tofacitinib; 3) switching/adding a new DMARD; 4) increasing of the dose of the starting therapy; 5) use of glucocorticoid joint injections; and 6) increasing the dose of oral glucocorticoid. A patient's therapy was defined as not effective if at least one of the criterion occurred during the first year of follow-up. Results: 16,305 RA patients were included; 2,879 began therapy with DMARD, 13,345 with biologics and 81 with tofacitinib. Among all patients, 77.5% were female and the mean age was 56.2 years (standard deviation 12.6). Table 1 shows the proportion of patients that meet the individual criterion and that achieved effectiveness at the end of one-year follow-up. Conclusions: Similar rates of therapy effectiveness were observed among groups, although the rates for the individual criteria differed. Fewer patients initiating biologic agents were non-adherent compared to DMARD and tofacitinib therapy, but switch/adding and injections tended to be higher in this group.
